Goldman Sachs' discussions with hospitals and industry participants suggest that the impact of the new price controls is likely to be minimal across most multi-specialty hospital chains.
Goldman Sachs' discussions with hospitals and industry participants suggest that the impact of the new price controls is likely to be minimal across most multi-specialty hospital chains.
<iframe src="https://hindustansphere.com/embed/cluster/0b9012ae4761c3674d9d5c636c59c7dbf19bb5d0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Hospital Stocks In Focus: Analysts See Limited Earnings Hit From 30% Cancer Drug Margin Cap"></iframe>
